Skip to main content
Erschienen in: International Cancer Conference Journal 1/2021

19.09.2020 | Case report

Unresectable hilar cholangiocarcinoma treated with chemoradiotherapy: a 9-year survival case

verfasst von: Takeshi Sakata, Takahiro Yoshikawa, Takeo Nomi, Yasuko Matsuo, Naoki Kamitani, Daisuke Hokuto, Masayuki Sho

Erschienen in: International Cancer Conference Journal | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Patients with advanced unresectable hilar cholangiocarcinoma have poor prognosis, and the survival is usually short. Herein, we report a 9-year survival case of unresectable hilar cholangiocarcinoma treated with chemoradiotherapy. A 64-year-old male patient presented with hilar cholangiocarcinoma. The tumor was located in the right hepatic duct, and it extended from the bifurcation of the anterior and posterior branches to the periphery. In the left side, the tumor extended from the umbilical portion to B2 and B3. However, there was no distant metastasis. The patient was then diagnosed with locally advanced, unresectable hilar cholangiocarcinoma and was treated with chemoradiotherapy. He received a total dose of 60 Gy in 30 daily fractions via intensity-modulated radiation therapy. In addition, he received gemcitabine chemotherapy for 5 years. There has been neither re-elevation of carbohydrate antigen 19-9 levels nor tumor relapse for 5 years during chemotherapy. Therefore, gemcitabine treatment was discontinued. However, the patient experienced tumor relapse 3 years after the last chemotherapy. Hence, chemotherapy with gemcitabine and cisplatin was initiated. At present, 1 year has passed after treatment for recurrence, and the patient has survived for 9 years since the initial treatment. Herein, we report a rare case of long-term survival with chemoradiotherapy in locally advanced unresectable hilar cholangiocarcinoma.
Literatur
1.
Zurück zum Zitat Igami T, Nishio T, Ebata T et al (2010) Surgical treatment of hilar cholangiocarcinoma in the ‘‘new era’’: the Nagoya experience. J Hepatobiliary Pancreat Surg 17:449–454CrossRef Igami T, Nishio T, Ebata T et al (2010) Surgical treatment of hilar cholangiocarcinoma in the ‘‘new era’’: the Nagoya experience. J Hepatobiliary Pancreat Surg 17:449–454CrossRef
2.
Zurück zum Zitat Miyazaki M, Kimura F, Shimizu H et al (2010) One hundred seven consecutive surgical resections for hilar cholangiocarcinoma of Bismuth types II, III, IV between 2001 and 2008. J Hepatobiliary Pancreat Sci 17:470–475CrossRef Miyazaki M, Kimura F, Shimizu H et al (2010) One hundred seven consecutive surgical resections for hilar cholangiocarcinoma of Bismuth types II, III, IV between 2001 and 2008. J Hepatobiliary Pancreat Sci 17:470–475CrossRef
3.
Zurück zum Zitat Nuzzo G, Giuliante F, Ardito F et al (2012) Improvements in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg 147:26–34CrossRef Nuzzo G, Giuliante F, Ardito F et al (2012) Improvements in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg 147:26–34CrossRef
4.
Zurück zum Zitat Matsuo K, Rocha FG, Ito K et al (2012) The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg 215:343–355CrossRef Matsuo K, Rocha FG, Ito K et al (2012) The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg 215:343–355CrossRef
5.
Zurück zum Zitat Ratti F, Cipriani F, Piozzi G et al (2015) Comparative analysis of left- versus right-sided resection in Klatskin tumor surgery: can lesion side be considered a prognostic factor? J Gastrointest Surg 19:1324–1333CrossRef Ratti F, Cipriani F, Piozzi G et al (2015) Comparative analysis of left- versus right-sided resection in Klatskin tumor surgery: can lesion side be considered a prognostic factor? J Gastrointest Surg 19:1324–1333CrossRef
6.
Zurück zum Zitat Burke EC, Jarnagin WR, Hochwald SN et al (1998) Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 228:385–394CrossRef Burke EC, Jarnagin WR, Hochwald SN et al (1998) Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 228:385–394CrossRef
7.
Zurück zum Zitat Ito F, Agni R, Rettammel RJ et al (2008) Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg 248:73–79CrossRef Ito F, Agni R, Rettammel RJ et al (2008) Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg 248:73–79CrossRef
8.
Zurück zum Zitat Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281CrossRef Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281CrossRef
9.
Zurück zum Zitat Park J, Kim MH, Kim KP et al (2009) Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 3:298–305CrossRef Park J, Kim MH, Kim KP et al (2009) Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 3:298–305CrossRef
10.
Zurück zum Zitat Li H, Zhang ZY, Zhou ZQ et al (2016) Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial. Oncotarget 7:26888–26897CrossRef Li H, Zhang ZY, Zhou ZQ et al (2016) Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial. Oncotarget 7:26888–26897CrossRef
11.
Zurück zum Zitat Engineer R, Mehta S, Kalyani N et al (2017) High dose chemoradiation for unresectable hilar cholangiocarcinomas using intensity modulated external beam radiotherapy: a single tertiary care centre experience. J Gastrointest Oncol 8:180–186CrossRef Engineer R, Mehta S, Kalyani N et al (2017) High dose chemoradiation for unresectable hilar cholangiocarcinomas using intensity modulated external beam radiotherapy: a single tertiary care centre experience. J Gastrointest Oncol 8:180–186CrossRef
12.
Zurück zum Zitat Chan SY, Poon RT, Ng KK et al (2005) Long-term survival after intraluminal brachytherapy for inoperable hilar cholangiocarcinoma: a case report. World J Gastroenterol 11:3161–3164CrossRef Chan SY, Poon RT, Ng KK et al (2005) Long-term survival after intraluminal brachytherapy for inoperable hilar cholangiocarcinoma: a case report. World J Gastroenterol 11:3161–3164CrossRef
13.
Zurück zum Zitat Becker G, Momm F, Schwacha H et al (2005) Klatskin tumor treated by inter-disciplinary therapies including stereotactic radiotherapy: a case report. World J Gastroenterol 11:4923–4926CrossRef Becker G, Momm F, Schwacha H et al (2005) Klatskin tumor treated by inter-disciplinary therapies including stereotactic radiotherapy: a case report. World J Gastroenterol 11:4923–4926CrossRef
14.
Zurück zum Zitat Kaido T, Imamura M (2005) Unresectable hilar cholangiocarcinoma completely reduced by external radiation therapy. Hepatogastroenterology 52:725–727PubMed Kaido T, Imamura M (2005) Unresectable hilar cholangiocarcinoma completely reduced by external radiation therapy. Hepatogastroenterology 52:725–727PubMed
15.
Zurück zum Zitat Ruys AT, van Haelst S, Busch OR et al (2012) Long-term survival in hilar cholangiocarcinoma also possible in unresectable patients. World J Surg 36:2179–2186CrossRef Ruys AT, van Haelst S, Busch OR et al (2012) Long-term survival in hilar cholangiocarcinoma also possible in unresectable patients. World J Surg 36:2179–2186CrossRef
16.
Zurück zum Zitat Mansour JC, Aloia TA, Crane CH et al (2015) Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford) 17:691–699CrossRef Mansour JC, Aloia TA, Crane CH et al (2015) Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford) 17:691–699CrossRef
17.
Zurück zum Zitat Gaspersz MP, Buettner S, van Vugt JLA et al (2017) Conditional survival in patients with unresectable perihilar cholangiocarcinoma. HPB (Oxford) 19:966–971CrossRef Gaspersz MP, Buettner S, van Vugt JLA et al (2017) Conditional survival in patients with unresectable perihilar cholangiocarcinoma. HPB (Oxford) 19:966–971CrossRef
Metadaten
Titel
Unresectable hilar cholangiocarcinoma treated with chemoradiotherapy: a 9-year survival case
verfasst von
Takeshi Sakata
Takahiro Yoshikawa
Takeo Nomi
Yasuko Matsuo
Naoki Kamitani
Daisuke Hokuto
Masayuki Sho
Publikationsdatum
19.09.2020
Verlag
Springer Singapore
Erschienen in
International Cancer Conference Journal / Ausgabe 1/2021
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-020-00445-z

Weitere Artikel der Ausgabe 1/2021

International Cancer Conference Journal 1/2021 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.